Australia · Delayed Price · Currency is AUD Acrux Company Description
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally.
The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names.
It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services.
The company was incorporated in 1998 and is based in West Melbourne, Australia.
| Country | Australia |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | John Warmbrunn |
Contact Details
Address: 103-113, Stanley Street West Melbourne, VIC 3003 Australia | |
| Phone | 61 3 8379 0100 |
| Website | acrux.com.au |
Stock Details
| Ticker Symbol | ACR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ACR3 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Felicia Colagrande B.Sc., BSc (Hons), M.B.A. | Product Development and Technical Affairs Director |
| Mark Hyman | Project and Technical Development Director |
| Dr. Jolanta Airey M.D. | Chief Medical Officer |